Published in Cancers (Basel) on April 30, 2015
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | NCT01449461
Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors | NCT01401504
Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol (2016) 0.96
Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology (2015) 0.86
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget (2016) 0.81
Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. Oncotarget (2016) 0.79
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol (2017) 0.77
The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist Updat (2016) 0.75
Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy. PLoS One (2016) 0.75
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers. Onco Targets Ther (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97
Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res (1999) 3.46
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov (2014) 3.31
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol (2013) 2.90
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell (2011) 2.88
Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res (2009) 2.65
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med (2013) 2.65
Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol (2010) 2.63
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med (2014) 2.26
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer (2014) 2.08
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res (2011) 2.06
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res (2011) 1.85
Crizotinib in anaplastic large-cell lymphoma. N Engl J Med (2011) 1.79
Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem (2001) 1.71
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev (2014) 1.56
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol (2015) 1.50
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res (2014) 1.48
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol (2014) 1.48
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res (2012) 1.42
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol (2014) 1.41
Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer (2012) 1.35
Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol (2006) 1.30
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol (2014) 1.30
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett (2014) 1.27
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem (2002) 1.25
ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer (2010) 1.24
ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol (2012) 1.07
Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther (2014) 1.03
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther (2011) 0.97
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist (2015) 0.96
LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. J Med Chem (2013) 0.89
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. J Thorac Oncol (2014) 0.87
Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation. J Thorac Oncol (2013) 0.86
Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Med Oncol (2015) 0.78
Primary oesophageal Ki (CD30)-positive ALK+ anaplastic large cell lymphoma of T-cell phenotype. Singapore Med J (2008) 0.78
Novel mutations in a patient with ALK-rearranged lung cancer. N Engl J Med (2014) 0.78